Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Transformational Data Sharing ETF (BLOK) vs Gilead Sciences, Inc. (GILD) Price & Performance

Amplify Transformational Data Sharing ETFTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Amplify Transformational Data Sharing ETF vs Gilead Sciences, Inc. — how do they compare? Amplify Transformational Data Sharing ETF trades at $58.96, while Gilead Sciences, Inc. trades at $135.98 (market cap $164.99B). The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Amplify Transformational Data Sharing ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.

BLOKGILD
52-Week High
$74.10$155.80
52-Week Low
$47.36$110.56
Market Cap
$164.99B
Sector
Health
Enterprise Value
$188.06B
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Transformational Data Sharing ETF

BLOK trades at $59.89 with minimal daily movement (+0.4%). Technical indicators show a bearish trend with all 13 moving averages signaling sell, while oscillators remain neutral. The stock faces resistance at $60 and support at $59. Recent news highlights the ETF's diversified blockchain economy exposure and inclusion of SpaceX shares following its historic IPO.

The outlook remains cautious due to strong bearish technical signals and sector volatility. Investment opportunity lies in diversified blockchain economy exposure, but risks include market sentiment shifts and competitive ETF landscape. Wall Street sentiment appears mixed with technical weakness offset by strategic positioning in growing sectors.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplify Transformational Data Sharing ETF

The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.

Read more on BLOK

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD